Sugi Predict

Sugi Predict / Compounds / SCHEMBL2303199

SCHEMBL2303199

SCHEMBL2303199

O=C1NCCN1c1ccc(S(=O)(=O)Nc2ccc(F)c(F)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ GFER P55789 2/20 0.53
▸ MAPT P10636 3/20 0.47
▸ PKM P14618 3/20 0.46
▸ KMT2A Q03164 5/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ FFAR4 Q5NUL3 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ TP53 P04637 2/20 0.43
▸ ESR1 P03372 1/20 0.43
▸ ADRB2 P07550 1/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ ADRB3 P13945 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ POLB P06746 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14217389 0.90 PKM (0.55) LMNASMN1; SMN2GFERMAPTPKM
SCHEMBL2300518 0.87 MAPT (0.61) LMNASMN1; SMN2MAPTPKMKMT2A
SCHEMBL2305062 0.84 CES1 (0.58) MAPTKMT2AMEN1ALDH1A1HTT
SCHEMBL2302292 0.83 PKM (0.67) LMNASMN1; SMN2MAPTPKMKMT2A
SCHEMBL2303492 0.82 MEN1 (0.58) LMNAMAPTPKMKMT2AMEN1
SCHEMBL2301965 0.81 ALDH1A1 (0.60) LMNAGFERMAPTPKMKMT2A
SCHEMBL2302229 0.81 HTR6 (0.47) LMNASMN1; SMN2MAPTPKMKMT2A
SCHEMBL2301221 0.81 IDO1 (0.50) LMNASMN1; SMN2MAPTPKMKMT2A
SCHEMBL14239653 0.81 MAPT (0.47) LMNASMN1; SMN2GFERMAPTPKM
SCHEMBL2307259 0.81 LMNA (0.58) LMNASMN1; SMN2PKMALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 — — US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 — — US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 — — US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 — — EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 — — US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 — — US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 — — US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 LMNA 2765/4885SMN1; SMN2 2479/4885GFER 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.